Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/217696
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Multitarget Virtual Screening for Drug Repurposing in COVID19 |
Autor: | Sorzano, Carlos Óscar S.; Crisman, Enrique CSIC; Carazo, José M.; León, Rafael CSIC ORCID | Palabras clave: | COVID-19 Virtual drug screening Structural biology |
Fecha de publicación: | 17-jul-2020 | Editor: | ChemRxiv | Resumen: | Therapeutic or preventive research for coronavirus SARS-CoV2 is an extremely active topic of research since its outbreak in January 2020. In this paper we report the results from a virtual drug screening analysis that, to the best of our knowledge, is the widest work in terms of target proteins and compound library. Our study was focused on the repur- posing of currently commercialized drugs, and especially those that can interact with multiple viral proteins and several binding sites within each protein. Additionally, we performed a second virtual screening analysis in which we compared our results to the predicted binding a nities for the drugs currently in clinical trials. We show that the best molecules in our screening compares favourably to those in clinical trials, suggesting their suitability for therapeutic or preventive applications.Therapeutic or preventive research for coronavirus SARS-CoV2 is an extremely active topic of research since its outbreak in January 2020. In this paper we report the results from a virtual drug screening analysis that, to the best of our knowledge, is the widest work in terms of target proteins and compound library. Our study was focused on the repur- posing of currently commercialized drugs, and especially those that can interact with multiple viral proteins and several binding sites within each protein. Additionally, we performed a second virtual screening analysis in which we compared our results to the predicted binding a nities for the drugs currently in clinical trials. We show that the best molecules in our screening compares favourably to those in clinical trials, suggesting their suitability for therapeutic or preventive applications. | Versión del editor: | https://doi.org/10.26434/chemrxiv.12652997.v2 | URI: | http://hdl.handle.net/10261/217696 | DOI: | 10.26434/chemrxiv.12652997.v2 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
DrugRepurposing.pdf | 483,99 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
215
checked on 23-abr-2024
Download(s)
177
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons